Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13)

dc.contributor.author	Ugurel, O.M.
dc.contributor.author	Mutlu, O.
dc.contributor.author	Sariyer, E.
dc.contributor.author	Kocer, S.
dc.contributor.author	Ugurel, E.
dc.contributor.author	Inci, T.G.
dc.contributor.author	Ata, O.
dc.contributor.author	Turgut-Balik, D.
dc.date.accessioned	2021-12-21T08:40:40Z
dc.date.available	2021-12-21T08:40:40Z
dc.date.issued	2020
dc.identifier.issn	1418130
dc.identifier.uri	https://doi.org/10.1016/j.ijbiomac.2020.09.138
dc.identifier.uri	http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/1140
dc.description.abstract	SARS-CoV-2 has caused COVID-19 outbreak with nearly 2 M infected people and over 100K death worldwide, until middle of April 2020. There is no confirmed drug for the treatment of COVID-19 yet. As the disease spread fast and threaten human life, reposition
dc.description.sponsorship	The numerical calculations reported in this paper were fully/partially performed at TUBITAK ULAKBIM, High Performance and Grid Computing Center (TRUBA resources). This research received no specific grant from any funding agency in the public, commercial,
dc.language.iso	English
dc.publisher	Elsevier B.V.
dc.rights	All Open Access, Bronze, Green
dc.title	Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13)
dc.type	Article
dc.relation.journal	International Journal of Biological Macromolecules
dc.identifier.startpage	1687
dc.identifier.endpage	1696
dc.identifier.volume	163
dc.identifier.doi	10.1016/j.ijbiomac.2020.09.138
dc.relation.volume	163

Files in this item

Files	Size	Format	View
There are no files associated with this item.